The Recommended Formatting Style Of Research Papers On Oncotarget

Oncotarget is a free-access peer-reviewed journal that publishes papers on cancer, aging and beyond, on a weekly basis. “Oncotarget” institutes all molecules, pathways and cellular functions that are common in cancer and aging, cancer cells and microbes, lymphocytes and neurons, and neurodegeneration and atherosclerosis. The online journal publishes research papers on diverse topics such as endocrinology, cardiology, cell biology, pharmacology, and metabolism. Authors that publish their work on Oncotarget benefit from timely and constructive peer-reviews. This way, they are able to augment the impact of their research. Exceptional research and discoveries are shared rapidly and widely once the papers have been published. Allowing researchers from various specialties to contribute to the progress of science helps in eliminating the barriers and links existing in different fields of biomedical science. Download output styles at Endnote.com.

When writing manuscripts, authors are required to pay keen attention to the format and style requirements. Papers should be written in clear grammar, double-spaced and all pages should be numbered. Manuscripts should follow Oncotarget’s style, starting from the title page, abstract, introduction, results, discussion, methodology, abbreviations, author contributions, acknowledgements, conflicts of interest and funding. The title page should be written precisely without abbreviations. The title should include key words to make it easy to determine the nature of the subject matter. Authors are also required to include their full names and mailing address on the title page. The abstract should be brief, but highlight all the content of the manuscript. Abbreviations should be written in the abstract section. This page should have a summary of the purpose of study, the experimental techniques, results and data interpretation.

Significant data such as the number of test subjects, controls and the magnitude of activities should be outlined in the abstract section. All abbreviations should be explained at their first mention in the page, to ensure that their usage in text is understood. The introduction page should have a brief background literature of the subject under study. This should also be accompanied by a brief reference to the necessary articles to acquaint the reader with the research and findings. The results section should include the findings of data, which should be presented in tables and illustrations. These findings should be interpreted in the discussion page. Under the methodology section, authors should explain the research methods and include adequate sources of special chemicals or preparations used.

Read more: https://www.dovepress.com/oncotargets-and-therapy-journal

New Treatment for Multiple Sclerosis Found

New clinical trial results show that undergoing high-dose immunosuppressive therapy and then having the patient’s blood-forming stem cells transplanted brings on the reduction of relapsing-remitting multiple sclerosis (MS). MS is an autoimmune disease in which the central nervous system gets attacked by the immune system. The treatment is called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HTC). Five years after participants had received treatment; sixty-nine percent of them didn’t have any new brain lesions and did not experience symptoms of MS.

Studies have revealed that other methods of treatment have not been as successful as HDIT/HTC. The trial, named HALT-MS was funded by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID-sponsored Immune Tolerance Network (ITN) conducted the study, of which the five-year results appeared in the American Academy of Neurology’s journal Neurology. NIAID director Anthony S. Fauci said that the extended findings suggest that a one-time treatment with HDIT/HTC may be better than any long-term medication given to people with any type of MS. The purpose of the experiment was to remove the disease-causing cells and keep the immune system in its normal state.

Dr. Shiva Gopal Vasishita is a practicing neurologist at Voorhees, New Jersey who works with the Kennedy National Hospital. He is among the 34 doctors in the hospital who specialize in neurology. Dr. Shiva Vasishita has an experience of over 38 years of experience in his area of expertise. He received his medical degree from Government Medical School Nagpur in 1979.

Dr. Gopal Vasishita is a member of the practice group known as Eastern Neurodiagnostic Associates and is also an expert in psychiatry. Dr. Gopal Vasishita accepts various insurance plans which include: Horizon Blue Cross Blue Shield, Aetna, and Medicare. He is a certified neurologist, licensed to practice in New Jersey (his license number is 25MA55133). His current place of practice is 2301 Evesham Road, Pavilion 800 Suite 2009, Voorhees, NJ.

JeanMarie Guenot Brings Promising Cancer Therapies To Light

 

A longtime accomplished specialist with significant expertise in the biotechnology and pharmaceutical industries, JeanMarie Guenot is at this time working to develop innovative autoimmune therapies for the treatment of cancer.  Newson6 covered her work in their piece “Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies” found here.

 

With her more than 20 years experience, as noted on her biography page at Guenot LLC, JeanMarie Guenot has worked with all phases of companies from research and development to corporate and business-related expansion as well as venture capital. She initially trained in physical and medicinal chemistry with a focus on protein structure prediction, X-ray and NMR refinement and drug design.

 

Prior to her current role as president and chief executive at San Francisco-based Amphivena Therapeutics, Guenot founded a start-up ophthalmic company, SKS Ocular, which focused on developing ocular drug delivery technologies and therapeutics for glaucoma and ocular inflammation.

 

She held a variety of positions that included business advisor for Hoffmann-La Roche in Shanghai, China and Basel, Switzerland; vice president of corporate and business development at PDL BioPharma and managing venture capital investments at Atlas Venture where she was also took part in building life science companies.

 

JeanMarie Guenot received her Ph.D. from the University of California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.

 

Making use of Jeanmarie Guenot’s education and building on her broad experience, Amphivena Therapeutics is working to eliminate blood cancers by cultivating therapies that adjust to a patient’s immune system.

 

Last year, Amphivena Therapeutics made it known that the US Food and Drug Administration (FDA) has acknowledged and accepted an investigational new drug application for AMV564, the company’s lead drug candidate.

 

Guenot commented in a statement that the acceptance of the first clinical trial of AMV564 symbolizes a crucial advancement effort for the company to produce a necessary therapeutic alternative for acute myeloid leukemia (AML) patients and their medical doctors.

 

She added Amphivena Therapeutics anticipates beginning its AMV564 clinical development program and weighing the impending possibilities for patients.  Read more about JeanMarie’s partnership with Takeda on their website.